Table 2 Outcomes
Hospital mortality | 1-year follow-up mortality | |||||
|---|---|---|---|---|---|---|
Survivors | Non-survivors | p | Survivors | Non-survivors | p | |
Copeptin (pmol/L) | 24.79 (10.90–84.82) | 145.60 (52.21–588.50) | 0.01 | 23.82 (10.96–77.30) | 112.28 (25.10–418.27) | 0.02 |
HGF (pg/ml) | 355.24 (175.55–521.76) | 381.05 (189.95–736.65) | 0.73 | 345.53 (183.68–561.15) | 350.00 (175.05–555.08) | 0.68 |
Hs-cTnI at inclusion (ng/ml) | 0.70 (0.15–4.58) | 2.71 (0.53–22.16) | 0.10 | 0.72 (0.17–4.71) | 2.11 (0.28–9.97) | 0.61 |
Maximum peak Hs-cTnI (ng/ml) | 11.71 (2.64–35.58) | 9.85 (2.41–50.99) | 0.90 | 13.80 (2.50–38.54) | 5.15 (2.87–20.44) | 0.28 |
Creatine kinase at inclusion (UI/l) | 141.00 (108.00–429.50) | 176.50 (108.5–259.00) | 0.97 | 154.00 (114.00–443.50) | 159.50 (88.25–255.25) | 0.36 |